EXLCUSIVE: Orgenesis Tells Benzinga 'Metalmark Shall Receive a Royalty of 5% of the Net Revenue of Octomera's Cell Processing Services, for the Three Calendar Years 2025-2027'
EXLCUSIVE: Orgenesis Tells Benzinga 'Metalmark Shall Receive a Royalty of 5% of the Net Revenue of Octomera's Cell Processing Services, for the Three Calendar Years 2025-2027'
獨家：Orgenesis告訴本辛加：“在2025-2027的三個日曆年中，Metalmark將獲得Octomera細胞處理服務淨收入的5％的特許權使用費”
EXLCUSIVE: Orgenesis Tells Benzinga 'Metalmark Shall Receive a Royalty of 5% of the Net Revenue of Octomera's Cell Processing Services, for the Three Calendar Years 2025-2027'
獨家：Orgenesis告訴本辛加：“在2025-2027的三個日曆年中，Metalmark將獲得Octomera細胞處理服務淨收入的5％的特許權使用費”
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。